On 11 June 2019, the FDA extended its indication as a first-line therapy for patients with metastatic or unresectable, recurrent HNSCC, either as monotherapy in patients whose tumor expresses PD-L1 (combined positive score ≥ 1%) or in combination with platinum and fluorouracil (only for nonnasopharyngeal–Category 2A). Here, CD274 is linked to head and neck squamous cell carcinoma.